Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of rodents and humans. Its activation triggers acute pain, making drugs that target TRPM3 a potential approach to alleviate pain. Biohaven Ltd.’s BHV-2100 is the only selective TRPM3 antagonist in clinical development. The company recently disclosed the work leading to its discovery and early development, as well as the chemical structure.
Mabwell (Shanghai) Bioscience Co. Ltd. has announced that SST-001 (18F-FD4), an α-synuclein-targeted PET tracer developed by Mabwell’s incubated company Synusight Biotech, has received clinical trial clearance from China’s National Medical Products Administration (NMPA). The planned phase I trial will enroll healthy volunteers, patients with multiple system atrophy (MSA), and patients with Parkinson’s disease.
Abbvie Inc. is buying exclusive rights to develop, manufacture and commercialize two Nav1.8 inhibitors for pain – HSK-55718 and HSK-51155 – from Haisco Pharmaceutical Group Co. Ltd. for $30 million up front and up to $715 million in milestone payments, plus royalties.
Investigators have shown that REED1 expression was elevated during stress, which in turn suppressed hippocampal synaptogenesis and induced major depressive disorder (MDD)-like behavior through mTORC1 signaling. The impact of REDD1 modulation was investigated in the preclinical setting for MDD.
Quiver Bioscience Inc. has received a strategic investment from the Porta family office (Argentina) to advance the company’s antisense oligonucleotide (ASO) therapeutic program for chromosome 15q duplication (Dup15q) syndrome. The investment will fund preclinical activities, including safety studies for candidate selection as the program advances toward clinical development.
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and frontotemporal dementia (FTD). This fragment accumulates at synapses, disrupts glutamatergic signaling and contributes to cognitive impairment in vivo.
Haisco Pharmaceutical Group Co. Ltd. has entered into an exclusive licensing agreement with Abbvie Inc., granting Abbvie the exclusive rights to develop, manufacture and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong and Macau.
Realta Life Sciences Inc. raised an additional $40 million in the final tranche of its series A investment, bringing the total the company has raised to more than $150 million through mission-driven investors and a family-office model.
Researchers from the Cyprus Institute of Neurology and Genetics and collaborators report the development of a gene silencing therapy for Charcot-Marie-Tooth type 1A.
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) and HCN2 blockers potentially useful for the treatment of pain, tinnitus, neurological and mood disorders.
RSS
